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over	 30	 genes	 currently	 implicated.	 Previously	 the	 UK-	GAPP	 study	 using	 whole	
exome	sequencing	(WES)	identified	a	pathogenic	variant	in	19	of	47	(40%)	patients	of	
which	71%	had	variants	in	genes	known	to	cause	IT.
Aims:	To	employ	a	 targeted	next-generation	sequencing	platform	 to	 improve	effi-
ciency	of	diagnostic	testing	and	reduce	overall	costs.









5-	10	years,	we	 are	 discovering	 increasing	 numbers	 of	 novel	 genes	
and	variants	with	 a	 critical	 role	 in	platelet	 production,	 physiology,	
and	function.2–5
To	 date,	 there	 are	 30	 genes	 suspected	 to	 cause	 26	 separate	
forms	of	inherited	thrombocytopenia	making	genetic	diagnosis	com-
plex.6	 However,	 until	 recently,	 IT	 remained	 underdiagnosed	 with	
previous	studies	only	providing	a	genetic	diagnosis	in	just	over	50%	
of	 individuals.7–9	 A	 genetic	 diagnosis	 provides	 clinical	 benefits	 for	
the	patients.	Some	patients	with	a	reduced	platelet	count	have	had	











and	development	of	 a	 targeted	gene-	specific	 sequencing	platform	
will	provide	a	quick	and	cost	effective	screening	for	patients	with	IT.
As	new	sequencing	library-	capture	methods	are	developed,	the	
speed	of	 sample	 preparation	 time	 is	 vastly	 reduced.	 Thus,	 the	 re-
cently	 released	 capture	 methods,	 Illumina	 Nextera	 Rapid	 Custom	
Methods:	We	have	developed	an	IT-	specific	gene	panel	as	a	pre-	screen	for	patients	
prior	to	WES	using	the	Agilent	SureSelectQXT	transposon-	based	enrichment	system.
Results:	 Thirty-	one	 patients	 were	 analyzed	 using	 the	 panel-	based	 sequencing,	 of	
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and	 the	 increasing	 advances	 in	 custom	 panel	 next	 generation	 se-












takes	advantage	of	 a	 rapid	 sample	preparation	 technique	allowing	





All	 patients	had	a	bleeding	history	 taken	at	 the	point	of	 examina-
tion	and	inclusion	into	the	study.	Most	patients	suffered	from	mild	
bleeding	 symptoms	 including	 cutaneous	 bruising,	 bleeding,	 and	
epistaxis	 in	 addition	 to	 more	 severe	 bleeding	 symptoms	 in	 some	




participants	 gave	 written	 informed	 consent	 in	 accordance	 with	 the	
Declaration	of	Helsinki.	The	GAPP	study	was	registered	at	www.isrctn.
org	 as	 #ISRCTN	77951167	 and	 is	 included	 in	 the	National	 Institute	
of	 Health	 Research	 Non-	Malignant	 Haematology	 study	 portfolio,	
(ID-	9858).
2.2 | Platelet counts and morphology
Platelet	 counts	 and	 morphology	 were	 measured	 from	 patients	 in	
whole	blood	using	 the	Sysmex	XN-	1000	 (n	=	31).	The	PLT-	F	chan-
nel	was	used	to	determine	platelet	counts	 in	whole	blood	and	the	
immature	platelet	 fraction	 (IPF).	Mean	platelet	 volume	 (MPV)	was	
determined	 from	 the	 impedance	 PLT-	I	 channel.	 All	 samples	 were	
processed	in	tandem	with	travel	controls.









2.4 | Thrombocytopenia- specific panel sequencing
A	thrombocytopenia	panel	was	designed	 for	use	as	an	 initial	NGS	
(NGS)	 sequencing/pre-	screen	 before	 whole	 exome	 sequencing	 in	
collaboration	with	the	Regional	Genetics	laboratory	at	Birmingham	
Women’s	Hospital.
The	 panel	 was	 designed	 using	 the	 Agilent	 SureDesign	 v3.5.4	
(Agilent	 Technologies,	 UK)	 design	 software.	 The	 original	 design	
included	 the	 following	 30	 genes;	 ABCG5,	 ABCG8,	 ADAMTS13,	
ANKRD18A,	ANKRD26,	CYCS,	FLI1,	FLNA,	FYB,	GATA1,	GFI1B,	GP1BA,	












also	 designed	 with	 the	 strictest	 masking	 stringency	 settings	 pos-
sible.	 SureDesign	masks	 repetitive	 sequences	dependent	on	 three	
masking	 tools:	RepeatMasker,	WindowMasker,	and	Uniqueness	35	
track.	The	design	software	uses	combinations	of	all	 three	 tools	 to	
create	three	masking	stringencies	which	vary	in	their	inclusiveness	
of	 repeat	 regions.	 If	baits	 could	not	be	 found	 in	 the	highest	 strin-
gency	possible,	stringency	was	decreased	until	they	could	be	found.	
Eighteen	genes	were	covered	entirely	using	the	highest	stringency	
setting,	 eight	 genes	 were	 covered	 by	 a	 combination	 of	 high	 and	








genes	 implicated	 in	 IT.	 The	 second	version	of	 the	design	 included	
all	probes	from	the	first	design	with	the	addition	of	baits	designed	
to	sequence	the	following	genes;	ACTN1,	ETV6,	PF4,	and	PRKACG. 











48 5 M 125 9.1 NT P-	Selectin NT NT Cutaneous	bruising,	petechiae
49 41 M 30 NA 9.4 NT ADP Normal Cutaneous	bruising
50 41 M 30 NA 59.4+ CD42b NT NT Cutaneous	bleeding




52 43 F 131 8.7 14.7+ Normal AA Reduced Cutaneous	bleeding,	epistaxis,	
menorrhagia,	Gi	bleeding,	oral	
cavity	bleeding
53 27 F 104 9.1 NT Fibrinogen NT NT Cutaneous	bleeding
54 12 M 101 10 39.8+ P-	Selectin NT NT Cutaneous	bleeding
55 UNK F 30 8.6 2.3 P-	Selectin NT NT Cutaneous	bruising,	oral	cavity	
bleeding,	menorrhagia
56 15 F 48 10.2 45.2+ Normal NT NT Cutaneous	bleeding,	epistaxis
57 11 F 153 12.1 9.2 NT ADP,	AA Reduced Cutaneous	bruising/bleeding
58 9 F 82 8.6 6.4 P-	Selectin,	
Fibrinogen
NT NT Cutaneous	bruising/bleeding
59 4 M 94 12.3 7.1 Normal NT NT Cutaneous	bruising/bleeding
60 UNK F 146 13.4+ 15.8+ CD41 Adr Normal Cutaneous	bruising,	oral	cavity	
bleeding,	menorrhagia
61 UNK F 76 9.7 3.4 P-	Selectin,	
Fibrinogen
NT NT No	observable	phenotype
62 34 F 138 13.8+ 17.5+ Normal NT NT Cutaneous	bleeding
63 13 F 37 14.6+ 16+ P-	Selectin NT NT Cutaneous	bruising,	petechiae,	
epistaxis
64 UNK F 105 14.5+ 23.1+ NT Normal Normal Cutaneous	bruising,	epistaxis
65 35 F 52 14.9+ 19.4+ P-	Selectin,	
Fibrinogen
NT NT Cutaneous	bruising/bleeding
66 18 F 87 10 1.8 P-	Selectin,	
Fibrinogen
NT NT Cutaneous	bruising/bleeding
67 22 M 40 13.1+ 15.7+ NT Normal Normal Cutaneous	bruising/bleeding,	
epistaxis
68 17 M 191 NT NT NT NT NT Cutaneous	bleeding,	nose	
bleeds
69 26 M 69 NT NT NT NT NT Nose	bleeds
70 34 F 96 NT NT NT NT NT None,	incidentally	identified	
thrombocytopenia
71 50 M 128 NT NT NT NT NT None,	investigated	as	son	has	
thrombocytopenia




73 29 F 53 11.7 9.1 NT NT NT Cutaneous	bruising,	hematuria,	
oral	cavity	bleeding
74 72 M 50 8.4 NT P-	Selectin NT NT Cutaneous	bruising,	epistaxis
75 48 F 92 NT NT NT NT NT Cutaneous	bruising,	hematomas
76 UNK F 92 10.2 NT Fibrinogen NT NT No	observable	phenotype
(Continued)







target	 enrichment	 kit	 for	 Illumina	multiplexed	 sequencing	 (Agilent	
Technologies).	Sample	preparation	followed	the	workflow	outlined	
in	 the	 manufacturer’s	 instructions	 (Figure	1).	 Due	 to	 the	 relative	














#5067-	5585	 for	 HS	 D1000	 reagents)	 (Agilent	 Technologies).	
Dynabeads	MyOne	Streptavidin	T1	magnetic	beads	were	used	for	
hybrid	 capture	 (ThermoFisher,	 #65601).	 Index	 tags	 were	 added	
using	the	SureSelectQXT	P7	and	P5	dual	indexing	primers.	All	ther-
mocycling	 steps	 were	 performed	 using	 a	 Bio-	Rad	 DNA	 Engine	
Tetrad	2	Thermal	Cycler	 (Bio-	Rad,	UK).	Magnetic	 separation	was	
achieved	using	a	DynaMag-	96	Side	magnet	(ThermoFisher).
Samples	were	 then	pooled	 for	multiplexed	 sequencing	 so	 that	









of	 10-	pmol/L	 DNA	 was	 used.	 DNA	 was	 firstly	 denatured	 by	
the	 addition	 of	 5	μL	 of	 0.2	mol/L	 NaOH	 to	 5	μL	 of	 4	nmol/L	
pooled library and allowed to incubate at room temperature 
(~20°C)	for	5	minutes	before	adding	990	μL	of	pre-	chilled	HT1	
hybridization	 buffer	was	 added	 to	 achieve	 a	 20-	pmol/L	 solu-
tion. A 300- μL	 aliquot	 of	 the	20-	pmol/L	 solution	was	diluted	
with 300 μL	HT1	to	achieve	a	final	concentration	of	10	pmol/L	
in 600 μL.
Finally	 sequencing	 was	 performed	 using	 an	 Illumina	 MiSeq	
(Illumina,	 UK)	 and	 MiSeq	 v2	 300	 Cycle	 Reagent	 Kits	 (Illumina,	
#15033626).	 Sample	 sheets	were	designed	 to	 allow	 for	 the	use	of	
custom	 primers	 and	 no	 adaptor	 trimming.	 Sequencing	 followed	 a	
Nextera	XT	sample	preparation	kit	and	amplicon	chemistry.
Sequence	 alignment,	 annotation,	 categorisation	 and	 variant	
calling	 was	 performed	 using	 the	 SureCall	 v3.5	 software	 (Agilent	
Technologies)	 and	 the	 GenAligners	 3.0	 alignment	 tool	 (Agilent	
Technologies).	 Post	 aligned,	 annotated,	 and	 categorized	 sequence	
data	was	analyzed	using	a	personalized	bioinformatics	pipeline	as	dis-
cussed	below.






variants	 not	 predicted	 to	 change	 the	 amino	 acid	 sequence	 in	 the	














77 15 F 76 9.4 13.5+ Normal NT NT Oral	cavity	bleeding,	
menorrhagia
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filtered	dependent	on	their	genomic	location	within	the	coding	re-
gion	 ±10	bp	 of	 intron-	exon	 boundaries.	 The	 UTRs	 were	 included	
in	bait	 design	 to	 allow	detection	of	 variants	within	 the	5′	UTR	of	
ANKRD26	so	that	all	variants	occurring	within	the	5′UTR	of	genes	
were	analyzed	individually.	Candidate	variants	identified	were	scru-
tinized	 using	 the	 same	 in	 silico	 pathogenicity	 prediction	 software	
and	variant	classification	system	as	candidates	from	WES	analysis	
as	outlined	previously.12	Finally,	pathogenicity	of	variants	was	de-




2.6 | Quality of sequence data, average number of 
variants, and sequence coverage
All	 individual	 DNA	 samples	were	 processed	 and	 passed	QC	 at	
two	 points	 during	 sample	 preparation.	 Prior	 to	 sample	 pooling	
an	average	calibrated	DNA	concentration	of	2.957	ng/μL	and	a	
molarity	of	13.3	nmol/L	was	observed	across	all	samples.	All	se-
quencing	 runs	passed	 internal	QC	that	 is	used	within	 the	West	
Midlands	Regional	Genetics	Service	at	the	Birmingham	Women’s	
Hospital	 and	 internal	 QC	 from	 the	 SureCall	 analysis	 software.	




3.1 | Phenotyping of IT patient cohort recruited to 
the study
All	 31	 unrelated	 cases	 included	 in	 this	 study	 underwent	 clinical	
evaluation	 to	 exclude	 idiopathic	 thrombocytopenic	 purpura	 (ITP)	
(following	a	relatively	stable	reduced	platelet	count	over	time)	and	




herited	 thrombocytopenia	 of	 unknown	 etiology	 (Table	1).	 Platelet	
counts	 varied	 between	 30	 and	 162	×	109/L	 among	 the	 31	 indi-
viduals	with	a	mean	count	of	88	×	109/L	(Table	1)	 (normal	range	to	
two	 standard	 deviations	 147-	327	×	109/L,	 n	=	40).	 Patients	with	 a	
platelet	 count	 between	 150-	200	×	109/L	were	 retained	 for	 analy-
sis	within	 the	study	under	 the	stipulation	 that	 there	was	a	 shared	
phenotype	 within	 the	 patient	 and	 related	 affected	 family	 mem-

















Prepared DNA library amplicons
Genomic locations of interest
Design target sequences in
SureDesign
SureSelect Capture Library
Hybridize using SureSelect Capture Library
Capture Library/prepared DNA library hybrids
Capture hybrids on streptavidin-coated
magnetic beads
Captured,target-enriched DNA library
PCR amplify using Dual
Indexing primers
Dual-indexed, target-enriched DNA library
Pool libraries for multiplex sequencing
SureSelect-enriched dual-indexed NGS samples
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LTA	was	used	 to	assess	platelet	 function	 for	 seven	patients	 and	
flow	cytometry	 alone	was	performed	 for	 samples	 from	17	patients.	
Platelets	 from	 individuals	 with	 a	 borderline	 platelet	 count	 in	 PRP	



















3.3 | Validation of IT- specific NGS panel
Validation	of	the	IT-	specific	NGS	panel	was	performed	by	ana-
lyzing	 the	 panel’s	 sensitivity	 in	 detecting	 eight	 variants	 iden-
tified	 previously	 by	 WES	 analysis	 and	 confirmed	 by	 Sanger	
sequencing.	 Variants,	 at	 the	 time	 of	 validation,	 were	 likely	
candidate	 variants	 and	 include	 variants	 in	 genes	 not	 known	
previously	 to	 cause	 IT	 (see	 Table	2).	 All	 variants,	 excluding	 a	
previously	 identified	 frameshift	 causing	 insertion	 in	 TUBB1; 
c.1080_1081insG,	p.Leu361Alafs*19	previously	identified	using	
WES	 in	 patient	 31,12	 were	 successfully	 identified,	 presum-
ably	due	 to	 the	 sequence	context	around	 this	genomic	 region.	
All	 known	 candidate	 variants	 tested	 were	 the	 only	 candidate	
variants	 following	 bioinformatics	 analysis	 of	 panel	 sequencing	
results	in	each	patient.
3.4 | Candidate variants observed and variant 





























tion	 of	 rs111527738	which	was	 present	within	 the	 latest	 build	 of	
dbSNP.	Four	pathogenic	or	 likely	pathogenic	 variants	were	 identi-
fied	that	are	previously	known	to	cause	IT.	These	were	found	in	pa-
tients;	54	(GATA1;	c.1240T>C,	p.*414Arg+41),	59	(RUNX1;	c.386C>A,	
Patient Gene Variation Type
2 ANKRD26 c.-	126T>G 5′-	UTR
17 RUNX1 c.G236A,	pTrp79* Nonsense
20 RUNX1 c.G332A,	p.Gly108Ser Partial	heterozy-
gous	missense
21 RUNX1 c.427	+	1G>T Splice	site	variant





36 WAS c.G1456A,	p.Glu486Lys X-	linked	Missense
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p.Ala129Glu),	 70	 (GFI1B;	 c.503G>T,	 p.Cys168Phe),	 and	 64	 (MYH9; 
c.2152C>T,	p.Arg718Trp).3,15–17
Patient	54,	a	12-	year-	old	male	with	a	history	of	cutaneous	bleed-
ing	and	a	mild	 reduction	 in	platelet	count	 (101	×	109/L)	was	noted	












cell	 surface.	 To	 date,	 serological	 analysis	 using	 flow	 cytometry	 to	
analyze	 the	 presence	 of	 Lutheran	 on	 the	 erythrocyte	 cell	 surface	
has	not	been	undertaken	 in	patient	54.	Also	the	presence	of	giant	
occasional	macrothrombocytes,	 a	marker	of	 the	published	pheno-
type,	have	not	been	observed	 in	patient	54	 in	 routine	histological	
examination.
A	previously	 identified	 causative	 variant	was	noted	 in	RUNX1 
in	 patient	 59.	 The	missense	 variant,	 c.386C>A,	 p.Ala129Glu,	was	
found	in	addition	to	a	missense	variant	in	ITGA2B.	The	variant	has	
previously	been	reported	to	be	causative	of	FPD/AML	in	three	pa-
tients	 from	a	 single	pedigree.15	All	 three	patients	were	 identified	
with	 the	 p.Ala129Glu	 germline	 mutation	 causative	 of	 FPD/AML.	
All	 patients	 developed	 AML	 as	 a	 result	 of	 a	 secondary	 somatic	
event	 occurring	within	RUNX1	 progressing	 to	 patient	 death	 in	 all	
cases.	Patient	59	 is	a	male	with	a	mild	reduction	 in	platelet	count	
to	94	×	109/L.	 Following	platelet	 function	 testing	 no	 reduction	 in	
platelet	secretion	(a	hallmark	of	variants	within	RUNX1)	was	noted.	
However,	 it	 is	highly	 likely	 that	 the	variant	observed	 in	RUNX1	 is	
causative	 of	 the	 hemostatic	 phenotype	 observed.	 Whether	 the	
variant within ITGA2B	 is	 additive	 to	 the	 phenotype	 is	 unlikely	 as	











ondary	 symptoms	have	previously	 been	 reported	 in	 patient	64	or	
any	of	the	affected	family	members	also	recruited	to	the	UK-	GAPP	
study.	However	patients	such	as	this	should	be	monitored	regularly	





3.5 | Conservation, pathogenicity prediction, and 
variant classification
Conservation	 at	 the	 site	 of	 variation	was	 determined	 by	 PhyloP	
and	PhastCons	in	silico	software.	Conservation	scores	for	all	vari-
ants	occurring	within	known	 IT-	causing	genes	 in	 the	31	patients	















patients	 where	 a	 genetic	 variant	 was	 identified	 this	 classification	








cost	 implications	 were	 an	 important	 consideration	 given	 that	 the	
WES	was	more	than	four	times	as	expensive	compared	with	targeted	
panel	sequencing.




capture	method,	 Agilent	 SureSelectQXT	 sample	 preparation	 does	
not	quite	reach	optimum	depth	of	coverage,	evenness	and	target	
enrichment	 when	 compared	 with	 alternate	 methods	 of	 capture	
including	 Agilent	 SureSelectXT.10,18	When	 applied	 to	 our	 custom	
designed	 panel,	 average	 coverage	 easily	 exceeded	 a	 universally	




in	 coverage,	which	 is	why	 in	WES	analysis	 the	gene	was	manually	
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TABLE  3 Variants	identified	by	analysis	of	the	IT-	specific	next-	generation	sequencing	pane
Patient Gene(s) Genomic variation Protein effect Variation type Prevalence PhyloP
48 ABCG5 c.293C>G p.Ala98Gly Missense 0.005	(rs145154937) 5.277
ABCG8 c.1667T>C p.Phe556Ser Missense 0.0009	(rs548098742) 2.914
TUBB1 c.-	88G>C 5′UTR	start	gain 0.004	(1000G)	(rs150072434)
49 ABCG5 c.1864A>G p.Met622Val Missense 0.00541	(rs140374206) −0.748
NBEAL2 c.6631G>A p.Asp2211Asn Missense Novel 5.515
50 CYCS c.155C>T p.Ala52Val Missense Novel 5.962
GP1BB c.del120- 142 p.Arg42Cys	fs*14 Frameshift	deletion Novel
51 FLI1 c.812G>A p.Arg271Gln Missense Novel 5.983
MYH9 c.2872G>A p.Ala958Thr Missense 0.0009	(rs151036570) 6.088
52 FLNA c.5948C>T p.Ser1983Leu Missense 0.0026	(rs187029309) 5.952
53 FLNA c.7583A>T p.Asp2528Val Missense Novel 4.858
MYH9 c.7C>G p.Gln3Glu Missense 0.0015	(rs56200894) 4.643
TUBB1 c.1199G>A p.Ser400Asn Missense Novel 5.88
54 GATA1 c.1240T>C p.*414Arg+41 Stop	loss Known 2.408
55 GP1BA c.206C>T p.Pro69Leu Missense 0.001872	(rs138825640) −1.407
56 GP1BB c.242T>G p.Leu81Arg Missense Novel −0.162
57 GP5 c.867G>C p.Met289Ile Missense 0.003101	(rs142440028) 2.516
58 GP5 c.867G>C p.Met289Ile Missense 0.003101	(rs142440028) 2.516
STIM1 c.182A>G p.Glu61Gly Missense 0.00004941	(rs202160755) 2.851
59 ITGA2B c.886G>A p.Gly296Arg Missense Novel 3.205
RUNX1 c.386C>A p.Ala129Glu Missense Known	(rs267607026) 6.077
60 ITGA2B c.2176A>T p.Lys726* Nonsense Novel 1.419
61 ITGA2B c.2417G>A p.Ser806Asn Missense Novel 0.148
WAS c.995T>C p.Val332Ala Missense 0.0051	(rs2737799) 0.096
62 MKL1 c.569C>T p.Pro190Leu Missense 0.00016	(rs200309955) 3.693
63 MKL1 c.1492G>C p.Val498Leu Missense 0.000008638	(rs199750225) 2.138
64 MYH9 c.2152C>T p.Arg718Trp Missense Known 2.044
65 MYH9 c.5074G>A p.Ala1692Thr Missense Novel 4.087
66 MYH10 c.2987C>T p.Ala965Val Missense 0.0079 4.822
NBEAL2 c.4361C>T p.Thr1454Met Missense 0.0001 3.227
67 TUBB1 c.421G>A p.Gly141Arg Missense 0.00003295	(rs778975827) 5.803
68 ABCG8 c.1629G>T p.Arg543Ser Missense 0.0002	(rs201690654) 5.057
69 ACTN1 c.136C>T p.Arg46Trp Missense 0.00000827 5.532
70 GFI1B c.503G>T p.Cys168Phe Missense 0.0006011	(rs527297896) 4.334
71 RUNX1 c.86T>C p.Leu29Ser Missense 0.01629	(rs111527738) 0.683
NBEAL2 c.4085G>A p.Arg1362Gln Missense 0.00000829 1.666
GFI1B c.551G>C p.Arg184Pro Missense 0.00000746 1.433
72–78 Unknown
(Continued)
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Patient Phastcons Mutation taster PolyPhen- 2 SIFT Provean ACMG criteria Classification
48 1 D D D D PP3 Uncertain	significance
1 D D D D PP3 Uncertain	significance
Uncertain	significance
49 0 P B T N BP4 Uncertain	significance
0.997 D D D D PM2,	PP3 Uncertain	significance
50 1 D B D D PM2 Uncertain	significance
D PM2,	PP3,	PM4,	PP4 Likely	pathogenic
51 1 D D D D PM2,	PP3 Uncertain	significance
1 D B T N Uncertain	significance
52 1 P D D D Uncertain	significance
53 1 D D D D PM2,	PP3, Uncertain	significance
0.998 D B D N Uncertain	significance
0.972 D B D N PM2 Uncertain	significance
54 0.572 P PM4,	PS1,	PP5 Likely	pathogenic
55 0 P B D D Uncertain	significance
56 0.175 P D D D PM2,	PP4 Uncertain	significance
57 0.55 P B D D Uncertain	significance
58 0.55 P B D D Uncertain	significance
1 D B D D Uncertain	significance
59 0.999 D B D D PM2 Uncertain	significance
1 D D D D PP3,	PS1,	PS3 Pathogenic
60 0.957 D PM2,	PM4,	PVS1,	PP4 Pathogenic
61 0.286 P B T N PM2 Uncertain	significance
0 P B T N BP4 Uncertain	significance
62 0.987 D B T D Uncertain	significance
63 0.998 D B T N Uncertain	significance
64 1 D D D D PP3,	PS1,	PS3,	PM	
(segregation),	PP4
Pathogenic
65 1 D B T N PM2 Uncertain	significance
66 1 D B D D Uncertain	significance
0.999 D B T N Uncertain	significance
67 1 D D D D PP3 Uncertain	significance
68 1 D D D N PM2 Uncertain	significance
69 1 D D D D PS1,	PM2,	PP3 Likely	pathogenic
70 1 D D D D PS1,	PM2,	PP3 Likely	pathogenic
71 1 P D T N Uncertain	significance
1 P D T N Uncertain	significance
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quencing	 methodologies	 and	 potential	 advantage	 of	 panel-	based	
sequencing.
In	 total,	 candidate	variants,	 that	could	be	considered	 for	 fur-
ther	analysis,	were	identified	in	77%	of	individuals	when	analyzed	









ously	 identified	with	a	 low	MAF.	This	may	be	an	 indication	that	the	
variants	 are	 tolerated	 within	 the	 population	 and	 are	 not	 causative	
of	disease.	One	way	 to	determine	 this	would	be	 to	analyze	 the	co-	
























the	 difficulty	 of	 picking	 up	 such	 defects	 despite	 the	 routine	
pre-	screening	 for	 disorders	 such	 as	 BSS-	 and	 MYH9-	related	
disease	 (using	 flow	cytometry	or	 the	presence	of	granulocyte	






disease	 in	 seven	 patients.	With	 the	 exception	 of	 patients	 50	
and	 65,	who	 present	with	 the	 characteristic	 increase	 in	MPV	
to	 the	magnitude	of	observable	giant	platelets,	 the	 remaining	
patients	show	an	unaltered	MPV.	No	Döhle-	like	body	leukocyte	
inclusions	were	noted	on	peripheral	 blood	 smears	of	 patients	
64	and	65	and	no	patients	presented	with	secondary	symptoms	
relating	 to	 specific	 IT	 disorders.	 However	 it	 should	 be	 noted	
that	 not	 all	 MYH9	 defects	 are	 associated	 with	 the	 presence	
of	Dohle-	like	bodies	 in	 a	peripheral	blood	 smear.	The	defects	
identified	may	 therefore	be	 causative	of	non-	typical	 forms	of	
BSS-	and	MYH9-	related	IT	but	in	order	to	exclude	a	MYH9	de-






to	 the	 travel	control	 tested	simultaneously.	When	analyzed	by	
the	 IT-	specific	NGS	panel	 a	missense	 variant	was	 identified	 in	
ITGA2B.	This	variant,	c.2417G>A,	p.Ser806Asn,	 is	novel	within	
all	 databases	 but	 predicted	 benign	 and	 not	 well	 conserved	 at	











Interestingly	 a	 reduction	 in	 cell	 surface	 expression	 of	 CD42b,	
encoded by GP1BA,	was	noted	in	patient	50,	who	harbors	a	poten-
tially	deleterious	large	deletion	of	GP1BB	that	spans	two	previously	
reported	 disease-	causing	 variants.23,24	 Although	 not	 occurring	 in	






further	 conformational	 work	 to	 be	 determined	 disease	 causing.	
Further	work	would	focus	around	this	point	mainly,	utilizing	many	of	
the	biomarkers	of	disease	attributed	to	variants	in	certain	genes	and	





A	 possible	 lack	 of	 genotype–phenotype	 correlation	 shown	 in	
patients	 harboring	 variants	 in	 ITGA2B,	GP1BA,	 and	MYH9 in par-
ticular	 is	an	interesting	observation,	however,	further	work	would	
12  |     JOHNSON et al.
be	needed	 to	validate	 this.	The	possibility	 that	 these	variants	are	
disease	causing	rests	on	the	functional	confirmation	of	the	effect	
of	variation.	However,	if	causative,	the	patients	represent	a	unique	
subset	 of	 each	 individual	 disease	 that	 does	 not	 share	 the	 typical	
phenotypic	presentation	of	previous	cases.	The	likelihood	that	pa-
tients	 exist	without	 the	 secondary	 symptoms	 and	 qualitative	 de-
fects	in	platelet	function	attributed	to	these	disorders	is	therefore	
relatively	high.
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